AGM/EGMApr 27, 2026, 04:34 PM
GYRE 2026 AGM to Vote on Cullgen Merger Stock Issuance, Directors
AI Summary
GYRE Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026. Stockholders will vote on several proposals, including the election of two Class II director nominees, an advisory vote on executive compensation, and the ratification of Grant Thornton as the independent auditor. A key proposal involves approving the issuance of common stock for the conversion of Series B Preferred Stock, related to the previously announced $300 million all-stock acquisition of Cullgen Inc. The company also detailed board changes contingent on the merger's closing, including the appointment of Cullgen's CEO, Ying Luo, as GYRE's new CEO and President.
Key Highlights
- 2026 Annual Meeting of Stockholders scheduled for June 10, 2026, virtually.
- Stockholders to vote on common stock issuance for $300M Cullgen merger.
- Two Class II director nominees, David M. Epstein, Ph.D. and Dan Weng, M.D., up for election.
- Advisory vote on named executive officer compensation is on the agenda.
- Ratification of Grant Thornton as independent auditor for 2026.
- Grant Thornton audit fees: $721,505 for 2025, $713,362 for 2024.
- Upon merger close, Ying Luo (Cullgen CEO) to become GYRE CEO & President.
- Board size to be reduced to seven directors post-merger.